The Diagnostics Acquisition Machine That Somehow Still Grew Margins

Diagnosis: Fever. Treatment: Four Acquisitions Administered Simultaneously.

When a diagnostics company decides to scale, it has two choices: build organic network (slow, cashflow-efficient) or buy existing players (fast, expensive, complicated). Metropolis chose both. Simultaneously. With the same intensity of a surgeon performing a triple bypass while the patient is still arguing about anaesthesia.

Founded in 1981 by Dr Sushil Shah as a single pathology lab, Metropolis is today the second-largest diagnostics chain in India—leader in West and South, aggressive insurgent in North and East. The stock has compounded at 11% annually over three years despite 5-year annualised returns being negative (because CAGR means nothing when a stock does 130% in one year then dumps 40% in the next). Since IPO in April 2019, the company has issued a 1:2 bonus, conducted a 1:2 split, and now is approving a 3:1 bonus. Someone doesn’t trust their own stock price.

Q3 FY26 was the quarter where everything collided: Core Diagnostics acquisition (March 2025, ₹247 crore) still bleeding operational losses while its genomics centre was being set up. Dr Ahuja’s Pathology (May 2025, ₹35 crore) and Scientific Pathology (June 2025, ₹55–83 crore) still in ramp phase. Yet, organic business delivered +15% revenue growth, +29% EBITDA growth, and +52% PAT growth. The acquisition portfolio is supposed to dilute margins. Instead, it’s being absorbed like the company has a secret playbook. Let’s audit that playbook with the precision a diagnostician would demand.

The Diagnostics Value Chain in 140 Characters

Patient walks in (or calls for home collection). Blood/sample collected. Sample sent to lab hub. Tested. Results issued. Doctor consults. Patient treated. Metropolis earns money at every touchpoint except the last one (they don’t provide treatment, which is both honest and profitable).

Scale driver: Network reach and channel mix. Metropolis operates 4,536 service network points—collection centres, pathology labs, and rural outreach. 92% of network is asset-light (franchisee model). Revenue splits roughly 60% B2C (wellness, direct consumers) and 40% B2B (hospitals, corporate employers, diagnostic chains). Revenue per patient in Q3 was ₹1,149; revenue per test ₹546. The company conducted 7.3 million tests in Q3 from 3.5 million patient visits.

Category mix: Routine diagnostics is commoditised (zero moat, price wars with online discount players). Specialty diagnostics (oncology, genetics, complex diseases) carries 40% of revenue and margins of 25%+ (moat intact). TruHealth (preventive wellness) is the fastest-growing segment at +25% YoY in Q3. Genomics—delayed by equipment sourcing, now live from Jan 2026—is positioned as the next decade’s growth engine.

Competition: 3 lakh diagnostic centres in India. Most are unbranded, single-city operator labs. Hospital labs capture 40% of volumes. Online players (like 1mg, Practo) are cannibalising routine testing but have zero presence in complex/specialist segments. Metropolis’ moat is geography (750 towns), brand (doctor trust), quality (CAP accreditation), and now—post-acquisition integrations—data infrastructure in oncology and genetics.

Q3 FY26: The Numbers That Need Three Columns of Context